

Table 1 Patient characteristics in patients with acquired resistance

		n	(%)
Median age(range)		68	(20-87)
Gender	Male	57	(47.5)
	Female	63	(52.5)
Smoking status	Never	73	(60.8)
	Current/former	47	(39.2)
stage	IV	73	(60.8)
	Recurrent	40	(33.3)
	III	7	(5.8)
Histology	Adenocarcinoma	119	(99.2)
	other	1	(0.8)
ECOG-PS	0	24	(20)
	1	79	(65.8)
	2	12	(10)
	3	4	(3.3)
	4	1	(0.8)
EGFR mutation	19del.	66	(55)
	L858R	45	(37.5)
	others	10	(8.4)
Prior EGFR-TKIs	Gefitinib	36	(30)
	Erlotinib	47	(39.2)
	Afatinib	37	(30.8)
Median treatment period of prior EGFR-TKIs (months)		14	(1.9-90)
Reasons for acquired resistance	PD	112	(93.3)
	RECIST PD	104	(86.7)
	Clinical PD	60	(50)
	SD	8	(6.7)